ESSEX BIO-TECH1061.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, ESSEX BIO-TECH (1061.HK) trades at a P/E of 4.45x, P/B of 0.46x, P/S of 0.69x, and a dividend yield of 5.76%.
Longitudinal percentile comparison: P/E sits at the 1st percentile over the trailing 10Y window (vs. 4th percentile over 3Y); P/B sits at the 1st percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 2nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 12th percentile within its industry and the 14th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 6.23%, ranking at the 100th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 0.5 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 6.23% total shareholder yield, 5.76% is paid out as dividends and roughly 0.47% is implied to come from buybacks — both channels are meaningfully in play. ESSEX BIO-TECH operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 1061 · SEHK: 1061 · 1061
Want the full picture on whether ESSEX BIO-TECH (1061.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 4.45 | ||||||
| P/B (MRQ) | 0.46 | ||||||
| P/S (TTM) | 0.69 | ||||||
| Dividend Yield | 5.76% | ||||||
| Buyback + Div Yield | 6.23% |